Celldex Therapeutics Inc. research snapshot
CLDX AI stock analysis currently reads Celldex Therapeutics as a clinical-stage biotechnology company developing barzolvolimab, a KIT-targeting monoclonal antibody for mast cell-driven diseases led by chronic spontaneous urticaria (CSU) in phase 3. The stock closed at $39.11 on July 10, 2026, implying about $3.07 billion of equity value using 78.49 million shares. The company holds $451 million in cash against minimal debt, providing estimated runway into 2029. The main debate is whether barzolvolimab succeeds in phase 3 CSU trials, commercial adoption scales post-approval (potentially 2027), and whether the pipeline expands beyond CSU into cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis. This page is informational research and is not investment advice.
Current price
$39.11 close on July 10, 2026
Market cap
$3.07 billion using 78.49 million shares; price times shares verified with 0.01% variance via financial_rigor.py
AI score
42 / 100
Rating
Pioneering KIT-targeting antibody platform with a late-stage CSU asset, offset by pre-revenue status, single-asset dependency, high short interest, and binary phase 3 and regulatory outcomes
Trend status
Price is near the 52-week high of $40.30, up 44% YTD, with elevated volatility and above-average short interest near 10.4% of float
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Celldex develops antibody therapies targeting KIT and other receptors for mast cell-driven inflammatory and autoimmune diseases. The lead asset barzolvolimab (CDX-0159) is a KIT monoclonal antibody in phase 3 for CSU, with phase 2 expansion into cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis. | Medium |
| Moat | The moat comes from KIT biology expertise, barzolvolimab differentiation as a mast cell-depleting antibody versus current symptomatic CSU therapies, issued and pending patents, and first-mover position in targeting KIT for chronic urticaria. However, multiple competitors including Novartis (remibrutinib BTK inhibitor), Roche (Xolair biosimilars), and other KIT-targeting programs could narrow the advantage. | Low-medium |
| Management | Founder-led management with Anthony Marucci as CEO since founding, strong scientific leadership under Tibor Keler, and a recent chief commercial officer hire (Teri Lawver in Nov 2025) signaling preparation for potential barzolvolimab launch. Key risk is single-asset dependency and whether the team can expand the pipeline and diversify beyond CSU. | Medium |
| Financial trend | Balance sheet shows $451 million in cash against negligible debt, providing runway into 2029. TTM net loss of $284 million and annual R&D spending suggest disciplined but significant cash burn. Shareholders approved expanded equity incentive plans in June 2026, which could lead to dilution. | High |
| Valuation | At $39.11 and $3.07B market cap, CLDX trades at 6.7x book value with no PE ratio due to negative earnings. The enterprise value of $2.61B against zero revenue implies the market prices in significant barzolvolimab approval and commercial probability. Risk/reward is asymmetric: large upside if phase 3 succeeds, significant downside if it fails. | Low-medium |
| Technical trend | CLDX trades near its 52-week high of $40.30, up 72% over the past year and 44% YTD. The stock is above its 50-day moving average but near resistance at the $40 zone. RSI is elevated and short interest remains high at 10.4% of float. | Medium |
| Risk level | Key risks are phase 3 CSU trial failure, regulatory delay or rejection, commercial adoption below expectations, competitive pressure from remibrutinib and biosimilar Xolair, single-asset concentration, equity dilution, and elevated short interest of 10.4%. | Medium-high |
| AI confidence | High for cash position, share count, market cap math, and reported financials. Medium for pipeline probability-adjusted scenarios because approval timelines and commercial adoption depend on binary clinical outcomes. | High for financials, medium for scenarios |
| Investment certainty | Low to medium. Barzolvolimab has promising phase 2 data, but phase 3 CSU outcomes are binary and the stock already prices in partial approval probability. Investors need a clear thesis on trial success probability and post-approval commercial adoption. | Low-medium |
CLDX AI stock forecast
The CLDX AI stock forecast uses scenario ranges around the $39.11 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires successful barzolvolimab phase 3 CSU data, FDA approval (potential 2027-2028 launch), and pipeline expansion. The base case assumes approval but slower-than-expected commercial uptake. The bearish case assumes phase 3 failure or significant competitive erosion.
$80 to $120
More likely if barzolvolimab phase 3 CSU trials meet primary endpoints with strong safety, FDA approval follows in 2027-2028, peak sales estimates exceed $2 billion, pipeline expansion into atopic dermatitis and prurigo nodularis adds value, and CLDX avoids significant dilution.
$35 to $55
More likely if barzolvolimab is approved for CSU but initial uptake is gradual, competitive pressure from remibrutinib and Xolair biosimilars limits market share, cash burn continues at current pace, and pipeline programs advance more slowly than expected.
$8 to $20
More likely if phase 3 CSU data disappoints, barzolvolimab fails to show meaningful differentiation versus standard of care, FDA requires additional trials delaying approval by 2-3 years, or safety signals emerge that limit the addressable patient population.
CLDX AI technical analysis
CLDX AI technical analysis starts from the $39.11 July 10 close used for this July 13 static page. The stock is trading near its 52-week high at $40.30 after a strong YTD run. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $39.11 | Latest verified close used for this page as of the July 13, 2026 data cutoff. |
| Near support | $34 to $36 | Support zone around the 50-day moving average area based on recent price action. |
| Secondary support | $27 to $30 | The 200-day moving average area. A sustained break below would weaken the long-term technical setup. |
| Near resistance | $40 to $42 | The 52-week high zone at $40.30 and analyst consensus target area. A breakout above $42 with volume would signal continued momentum. |
| 50-day moving average | About $35 to $36 | Public technical sources showed CLDX above the 50-day moving average around the cutoff. |
| 200-day moving average | About $28 to $30 | CLDX is well above the 200-day moving average, supporting the bullish YTD trend. |
| Momentum | RSI elevated, trending | RSI was in the 60-70 range after the YTD run, reflecting strong but not yet overbought momentum. Stochastic and MACD indicators leaned bullish but caution is warranted near 52-week highs. |
| Volume | About 1.0 to 1.3 million shares average daily | Volume was above average on up days near the 52-week high. A breakout should be confirmed by continued participation. |
| Volatility | Beta 0.90, elevated biotech volatility | CLDX beta appears moderate but the stock has shown sharp moves on clinical data releases. Position sizing should account for binary event risk. |
| Invalidation | Close below $34, then $28 | A close below the 50-day area weakens the near-term momentum. A break below the 200-day area would challenge the bullish trend. |
CLDX AI trading strategy
The CLDX AI trading strategy is a rules-based framework, not personalized advice. It combines clinical pipeline evidence, technical confirmation, position sizing for binary event risk, and clear invalidation levels.
Track phase 3 CSU data readout timelines and regulatory milestones. Consider accumulating on weakness toward support zones if the clinical and cash runway thesis remains intact.
Binary clinical outcomes create gap risk. No position should be sized larger than what can tolerate a 50% loss. Define maximum loss before any catalyst event.
Look for CLDX to hold above the 50-day moving average and break above $40 to $42 resistance with improving volume. Confirmation should include positive clinical news flow and analyst support.
A failed breakout or daily close below the 50-day area should reduce confidence. A break below the 200-day area would signal a trend change.
Track phase 3 CSU enrollment completion, data readout timelines, cash runway updates, KOL feedback on barzolvolimab differentiation, and competitive landscape changes from remibrutinib and Xolair biosimilars.
Reduce or exit if the phase 3 trial design changes raise risk, cash runway shortens significantly, or competitive data weakens the barzolvolimab differentiation thesis.
Investment research summary
Celldex develops antibody therapeutics that target mast cell receptors to treat chronic inflammatory and autoimmune skin diseases. Patients pay for symptom relief from conditions like chronic urticaria where current options are inadequate.
The moat is built on KIT biology expertise, barzolvolimab first-in-class potential as a mast cell-depleting antibody, and issued patents. Differentiation comes from targeting the root cause (mast cells) versus symptomatic treatment. The moat is uncertain because competitors with different mechanisms (BTK inhibitors, anti-IgE biosimilars) could erode the addressable market.
The thesis can fail if phase 3 CSU data does not replicate phase 2 results, FDA requires additional trials or issues a complete response letter, commercial adoption is slow due to reimbursement or physician inertia, competitors launch with better profiles, or the company dilutes shareholders to fund operations.
Founder Tony Marucci has led Celldex since its 2004 founding, demonstrating long-term commitment. The scientific leadership under Tibor Keler is strong. The commercial team buildout with Teri Lawver signals preparation for a potential launch. Key risk is whether the team can successfully transition from R&D to commercial execution.
Celldex operates in the immunology and inflammatory disease market, specifically mast cell-mediated conditions. The trend favors targeted biologics over broad immunosuppressants. CSU alone affects 1-3% of the global population, with significant unmet need for patients who fail antihistamines and Xolair.
At $3.07 billion market cap with zero revenue and negative earnings, the stock prices in significant barzolvolimab approval probability. There is no traditional margin of safety. The payoff is asymmetric: large upside on success, deep downside on failure. Investors should size accordingly.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CLDX price | $39.11 close on July 10, 2026 | Yahoo Finance and StockAnalysis quote snapshots | July 13, 2026 |
| Market capitalization | $3.07 billion, verified as $39.11 x 78,490,000 shares | financial_rigor.py market cap verification and SEC filings | July 13, 2026 |
| Cash and short-term investments | $451 million as of Q1 2026 | StockAnalysis and Yahoo Finance, cross-verified with 0.05% variance | July 13, 2026 |
| Total debt | Negligible (debt/equity ratio 0.42%) | StockAnalysis balance sheet data | July 13, 2026 |
| TTM revenue | $865,000 | StockAnalysis and SEC filings | July 13, 2026 |
| TTM net loss | -$283.7 million, cross-verified with 0.06% variance | StockAnalysis and MarketBeat | July 13, 2026 |
| EPS (TTM) | -$4.29 | financial_rigor.py valuation verification | July 13, 2026 |
| Shares outstanding | 78.49 million (basic) | StockAnalysis and Yahoo Finance | July 13, 2026 |
| 52-week range | $19.72 to $40.30 | Yahoo Finance and StockAnalysis | July 13, 2026 |
| Short interest | 10.4% of float, approximately 4.3 days to cover | MarketBeat short interest data | July 13, 2026 |
This CLDX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong. Biotech stocks carry binary clinical and regulatory risk. Past stock performance does not guarantee future results.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
